We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-4.31%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$50.7M
AUM Growth
+$467K
Cap. Flow
+$2.78M
Cap. Flow %
5.5%
Top 10 Hldgs %
63.23%
Holding
28
New
5
Increased
5
Reduced
5
Closed
3

Top Buys

1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$976K
2
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$564K
3
TYME
Tyme Technologies, Inc. Common Stock
TYME
+$550K
4
DRRX
DURECT Corp
DRRX
+$339K
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$125K

Top Sells

1
COLL icon
Collegium Pharmaceutical
COLL
+$2.36M
2
MDXG icon
MiMedx Group
MDXG
+$1.56M
3
ALKS icon
Alkermes
ALKS
+$1.41M
4
PFE icon
Pfizer
PFE
+$1.11M
5
GILD icon
Gilead Sciences
GILD
+$1.05M

Sector Composition

1 Healthcare 73.46%
2 Consumer Staples 1.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$169B
$4.19M 8.27%
60,000
-15,000
-20% -$1.05M
GSK icon
2
GSK
GSK
$106B
$3.82M 7.54%
80,000
– –
PFE icon
3
Pfizer
PFE
$143B
$3.23M 6.37%
75,000
-25,000
-25% -$1.11M
ALKS icon
4
Alkermes
ALKS
$8.66B
$3.08M 6.09%
100,000
-50,000
-33% -$1.41M
ALKS icon
5
PUT
Alkermes
ALKS
$8.66B
$3.08M 6.09%
+100,000
New +$2.83M
AMYT
6
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$3.02M 5.97%
250,000
+50,000
+25% +$564K
MRK icon
7
Merck
MRK
$315B
$3M 5.93%
40,000
– –
AZN icon
8
AstraZeneca
AZN
$263B
$3M 5.93%
25,000
– –
BMY icon
9
Bristol-Myers Squibb
BMY
$124B
$2.96M 5.84%
50,000
– –
SPXU icon
10
CALL
ProShares UltraPro Short S&P 500
SPXU
$472M
$2.63M 5.19%
7,500
+5,000
+200% +$1.65M
IRWD icon
11
Ironwood Pharmaceuticals
IRWD
$637M
$2.61M 5.16%
200,000
– –
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
$2.23M 4.4%
500,000
– –
PFE icon
13
PUT
Pfizer
PFE
$143B
$2.15M 4.25%
+50,000
New +$2.22M
TYME
14
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$2.06M 4.07%
2,000,000
+500,000
+33% +$550K
ATRS
15
DELISTED
Antares Pharma, Inc.
ATRS
$1.82M 3.59%
500,000
– –
SQQQ icon
16
CALL
ProShares UltraPro Short QQQ
SQQQ
$2.36B
$1.73M 3.41%
1,600
+800
+100% +$809K
UVXY icon
17
CALL
ProShares Ultra VIX Short-Term Futures ETF
UVXY
$237M
$1.23M 2.42%
+200
New +$1.27M
AMRN
18
CALL
Amarin Corp
AMRN
$297M
$1.02M 2.01%
10,000
– –
VRTX icon
19
Vertex Pharmaceuticals
VRTX
$123B
$907K 1.79%
+5,000
New +$976K
GNLN icon
20
Greenlane Holdings
GNLN
$1.52M
– –
0
– –
VYNE icon
21
VYNE Therapeutics
VYNE
$25.6M
$556K 1.1%
22,222
-2,778
-11% -$108K
ADMS
22
DELISTED
Adamas Pharmaceuticals
ADMS
$491K 0.97%
100,000
– –
GMDA
23
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$392K 0.77%
100,000
+25,000
+33% +$125K
DRRX
24
DELISTED
DURECT Corp
DRRX
$320K 0.63%
+25,000
New +$339K
VIXY icon
25
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$207M
$285K 0.56%
625
-625
-50% -$287K
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Healthcare Value Capital held 28 positions worth $50.7M, up 0.93% from $50.2M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Healthcare Value Capital deployed $2.78M of net new capital in Q3 2021, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 5,000 shares worth $907K.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 88% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Alkermes, an estimated $1.41M trimmed.

  • Healthcare Value Capital's largest Q3 2021 buy was Vertex Pharmaceuticals: 5,000 shares worth $907K.
  • Healthcare Value Capital added most to Amryt Pharma plc American Depositary Shares in Q3 2021, an estimated $564K increase.
  • Healthcare Value Capital's biggest Q3 2021 reduction was Alkermes, cutting an estimated $1.41M.
  • Healthcare Value Capital fully exited Collegium Pharmaceutical in Q3 2021, selling an estimated $2.36M.
  • Healthcare Value Capital's ten largest holdings make up 63% of its $50.7M portfolio in Q3 2021.
  • Healthcare Value Capital opened 5 new positions and closed 3 in Q3 2021.
  • Healthcare Value Capital's portfolio value rose 0.93% quarter-over-quarter to $50.7M.

Based on Healthcare Value Capital's 13F filing for Q3 2021, filed 15 Nov 2021.